144 related articles for article (PubMed ID: 12713832)
21. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
Matter H; Schudok M; Schwab W; Thorwart W; Barbier D; Billen G; Haase B; Neises B; Weithmann K; Wollmann T
Bioorg Med Chem; 2002 Nov; 10(11):3529-44. PubMed ID: 12213468
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
23. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
[TBL] [Abstract][Full Text] [Related]
24. Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8.
Bianchini G; Aschi M; Cavicchio G; Crucianelli M; Preziuso S; Gallina C; Nastari A; Gavuzzo E; Mazza F
Bioorg Med Chem; 2005 Aug; 13(15):4740-9. PubMed ID: 15935680
[TBL] [Abstract][Full Text] [Related]
25. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.
Wada CK
Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of novel enzyme activity methods to assess inhibition of matrix metalloproteinases (MMPs) in human serum by antibodies against enzyme therapeutics.
Edkins TJ; Alhadeff JA; Kwok V; Kalensky C; Rock MT; Vidmar TJ; Del Tito BJ
J Pharm Biomed Anal; 2012 Nov; 70():408-14. PubMed ID: 22854133
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of novel oxazoline MMP inhibitors.
Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of conformationally-constrained MMP inhibitors.
Natchus MG; Cheng M; Wahl CT; Pikul S; Almstead NG; Bradley RS; Taiwo YO; Mieling GE; Dunaway CM; Snider CE; McIver JM; Barnett BL; McPhail SJ; Anastasio MB; De B
Bioorg Med Chem Lett; 1998 Aug; 8(16):2077-80. PubMed ID: 9873489
[TBL] [Abstract][Full Text] [Related]
31. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
Sheppard GS; Florjancic AS; Giesler JR; Xu L; Guo Y; Davidsen SK; Marcotte PA; Elmore I; Albert DH; Magoc TJ; Bouska JJ; Goodfellow CL; Morgan DW; Summers JB
Bioorg Med Chem Lett; 1998 Nov; 8(22):3251-6. PubMed ID: 9873712
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
Yan YL; Miller MT; Cao Y; Cohen SM
Bioorg Med Chem Lett; 2009 Apr; 19(7):1970-6. PubMed ID: 19261472
[TBL] [Abstract][Full Text] [Related]
33. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
Skiles JW; Gonnella NC; Jeng AY
Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of sulfur based inhibitors of matrix metalloproteinase-1.
Fujisawa T; Odake S; Ogawa Y; Yasuda J; Morita Y; Morikawa T
Chem Pharm Bull (Tokyo); 2002 Feb; 50(2):239-52. PubMed ID: 11848217
[TBL] [Abstract][Full Text] [Related]
35. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
36. Difluoroketones as inhibitors of matrix metalloprotease-13.
Reiter LA; Martinelli GJ; Reeves LA; Mitchell PG
Bioorg Med Chem Lett; 2000 Jul; 10(14):1581-4. PubMed ID: 10915056
[TBL] [Abstract][Full Text] [Related]
37. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
39. Matrix metalloprotease inhibitors: design from structure.
Borkakoti N
Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
[TBL] [Abstract][Full Text] [Related]
40. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
Fray MJ; Burslem MF; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
